Patents Examined by Amy Lewis
-
Patent number: 7132554Abstract: This invention relates to a synergistic therapeutic combination of anti-cancer compounds which comprises a) a taxane, and b) a substance that binds to the epidermal growth factor receptor (EGFR) and blocks the ability of epidermal growth factor (EGF) to intitiate receptor activities which results in tumor growth inhibition, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use.Type: GrantFiled: March 14, 2005Date of Patent: November 7, 2006Assignee: Bristol-Myers Squibb CompanyInventor: William C. Rose
-
Patent number: 7129256Abstract: A compound represented by the formula: wherein A is thiazolyl or the like, X is a bond or the like, m is an integer of 0 to 4, Y is optionally substituted alkyl or the like, Z is a substituent represented by the formula: wherein R3 is hydrogen atom or the like, R4 and R5 are each independently hydrogen atom or the like, W is —(CH2)n— (n is 0, 1, 2 or 3) or the like, a prodrug thereof, its pharmaceutically acceptable salt, or its solvate is useful as a composition for prevention or treatment of Parkinson's disease.Type: GrantFiled: August 29, 2001Date of Patent: October 31, 2006Assignee: Shionogi & Co., Ltd.Inventors: Shunji Shinohaea, Katsumi Koike
-
Patent number: 7122576Abstract: This invention is directed to a method for preventing or treating bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) or enantiomeric mixture wherein one enantiomer of Formula (I) predominates: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1–C4 alkyl; wherein C1–C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1–C4 alkyl, C1–C4 alkoxy, amino, nitro and cyano).Type: GrantFiled: February 21, 2002Date of Patent: October 17, 2006Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman, Yong Moon Choi, Robert Gordon
-
Patent number: 7115624Abstract: The present invention provides a method of inhibiting a member of a family of Protein Tyrosine Phosphatases (PTPases, PTPs) such as PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTP?, PTP?, PTP?, PTP?, PTP?, PTP?, PTP?, PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR, and HePTP by exposing said Ptpase member by administration to a host or otherwise to at least one compound with certain structural, physical and spatial characteristics that allow for the interaction of said compound with specific residues of the active site of PTP1B and/or TC-PTP. These compounds are indicated in the management or treatment of a broad range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignant diseases, and type I diabetes and type II diabetes, as well as in the isolation of PTPases and in elucidation or further elucidation of their biological function.Type: GrantFiled: September 11, 2000Date of Patent: October 3, 2006Assignee: Novo Nordisk A/SInventors: Henrik Sune Andersen, Thomas Kruse Hansen, Lars Fogh Iversen, Jesper Lau, Niels Peter Hundahl Møller, Ole Hvilsted Olsen, Frank Urban Axe, Yu Ge, Daniel Dale Holsworth, Todd Kevin Jones, Luke Milburn Judge, Wiliam Charles Ripka, Barry Zvi Shapira, Roy Teruyuki Uyeda
-
Patent number: 7115665Abstract: The present invention relates to the treatment of cancer with compounds that inhibit the activity of endo-exonuclease. Endo-exonuclease has been shown to be necessary for the repair of damaged DNA. Compounds that inhibit the activity of endo-exonuclease have been shown to be particularly effective for treating cancer when used in combination with drugs that induce DNA breaks such as cisplatin and mitomycin C. These compounds have a synergistic effect when used in combination for inhibiting tumour growth. The invention includes pharmaceutical compositions for inhibiting tumour growth comprising a compound that inhibits endo-exonuclease activity. These pharmaceutical compositions preferably include compounds that induce DNA breaks. The invention includes methods of treating cancer with these pharmaceutical compositions and uses of these compositions to treat cancer. The preferred compounds that inhibit the activity of endo-exonuclease have low toxicity. One such compound is pentamidine.Type: GrantFiled: November 16, 2000Date of Patent: October 3, 2006Assignee: Onocozyme Pharma, Inc.Inventors: Terry Chow, Chiaoli Yeh, David Griller, Leonard Yuen
-
Patent number: 7091226Abstract: The invention relates to the treatment of a proliferative disease, especially according to certain treatment regimens, with an epothilone, especially with epothilone A and more preferably epothilone B; as well as to the treatment of certain cancers with such an epothilone.Type: GrantFiled: March 24, 2005Date of Patent: August 15, 2006Assignee: Novartis AGInventors: Terence O'Reilly, Markus Wartmann, Manuel Litchman, Pamela Cohen
-
Patent number: 7087647Abstract: Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.Type: GrantFiled: October 30, 2002Date of Patent: August 8, 2006Assignee: Cephalon, Inc.Inventors: Matthew S. Miller, Thomas E. Scammell
-
Patent number: 7074834Abstract: A veterinary composition comprising a guanidine derivative, e.g., guanabenz or guanabenz acetate is provided which produces a rapid acting and long lasting sedative and analgesic effect in a subject animal that is selectively reversible. The use of guanabenz in the horse provides for a safe, effective, long lasting and rapidly reversible sedative and analgesic which can be used on the standing animal. Methods of use of the compositions of the invention are also provided.Type: GrantFiled: May 24, 2001Date of Patent: July 11, 2006Assignee: University of Kentucky FoundationInventor: Thomas Tobin
-
Patent number: 7074824Abstract: Beta-lapachone, which is poorly soluble in most pharmaceutically acceptable solvents, has demonstrated significant antineoplastic activity against human cancer lines. The present invention overcomes this significant limitation by teaching novel pharmaceutical compositions comprising a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, which may be at water-solubilizing carrier molecule such as hydroxypropyl-?-cyclodextrin, or an oil-based solubilizing carrier molecule, for enhancing the solubility of Beta-lapachone in aqueous solution. The therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, may be complexed with the pharmaceutically acceptable solubilizing carrier molecule in aqueous solution. The novel pharmaceutical compositions may be administered with a second anticancer agent or in combination with radiation therapy.Type: GrantFiled: July 31, 2002Date of Patent: July 11, 2006Assignee: Arqule, Inc.Inventors: Zhiwei Jiang, Dasharatha G. Reddy
-
Patent number: 7071228Abstract: A method of treating said musculoskeletal and connective tissue inflammations including osteoarthritis and associated articular and periarticular inflammations, and non-articular Rheumatism including capsulitis, tendonitis, fibrositis, and perarticular inflammations is disclosed. The method includes administering to a patient of a therapeutically effective amount of a composition comprising 13-cis-retinoic acid. Preferably, the treatment method includes administering to a patient of an initial dosage of a composition comprising 13-cis-retinoic acid for an initial treatment period, and thereafter administering a maintenance dosage of the composition.Type: GrantFiled: October 23, 2002Date of Patent: July 4, 2006Inventor: L. Dean Parks
-
Patent number: 7060828Abstract: This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.Type: GrantFiled: June 29, 2001Date of Patent: June 13, 2006Assignee: Inex Pharmaceuticals CorporationInventors: Thomas D. Madden, Sean C. Semple
-
Patent number: 7053065Abstract: A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.Type: GrantFiled: June 15, 2001Date of Patent: May 30, 2006Assignee: Eli Lilly and CompanyInventors: Clet Niyikiza, Paolo Paoletti, James Jacob Rusthoven
-
Patent number: 7041642Abstract: Light emitting compounds of the formula: where R1 is a light-emitting moiety, R2 is a bombesin-like peptide and fragment, derivative or analog thereof and L is a linker moiety, which may be present or absent. The peptide is linked at a first amino acid position to (C—X) which, in turn, is selected from the group including C?O, C?S, CH(OH), C?C=O, C?NH, CH2, CH(OR), CH(NR), CH(R), CR3R4, and C(OR3)OR4 where R, R3, and R4 are alkyl moieties or substituted alkyl moieties. Optionally the compound may include a linker moiety between the peptide and the C—X binding group. Preferably, the compound exhibits substantial biological activity in the presence of receptors having affinities for bombesin-like peptides.Type: GrantFiled: July 12, 1999Date of Patent: May 9, 2006Assignee: PerkinElmer LAS, Inc.Inventors: Clarissa Desjardins, Jacek Slon-Usakiewicz, Katherine J. Bonter
-
Patent number: 7041699Abstract: A nutrient pharmaceutical formulation composition useful for treating cancer comprising ascorbic acid, L-lysine, L-proline and at least one polyphenol compound selected from the group consisting of epigallocatechin gallate, epicatechin gallate, epigallocatechin, epicatechin, catechin and the use of the composition in treating cancer and other tumors are provided.Type: GrantFiled: January 13, 2003Date of Patent: May 9, 2006Assignee: Matthias RathInventors: Shrirang Netke, Aleksandra Niedzwiecki, Matthias Rath, Waheed M. Roomi
-
Patent number: 7029659Abstract: A topical mousse composition including an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.Type: GrantFiled: January 27, 2004Date of Patent: April 18, 2006Assignee: Connetics Australia Pty Ltd.Inventor: Albert Zorko Abram
-
Patent number: 7018982Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.Type: GrantFiled: March 18, 2003Date of Patent: March 28, 2006Assignee: NPS Allelix Corp.Inventors: John Dietrich, Sverker Ljunghall, Sven Sjögren
-
Patent number: 7015253Abstract: The present invention provides treatment regimens for treating diseased prostate tissue, including the steps of chemically ablating prostate tissue and coadministering an antiandrogen. In some embodiments, prostate tissue is chemically ablated by injection of ethanol, or an injectable gel comprising ethanol, into prostate tissue. Steroidal and non-steroidal antiandrogens are suitable antiandrogens. One suitable non-steroidal antiandrogen is bicalutamide. The treatment regimen is suitable for treatment of prostate tissue diseases including benign prostatic hyperplasia and prostatic carcinoma. The invention further provides a treatment regimen for treating benign prostatic hyperplasia, including the steps of damaging prostate tissue and coadministering an antiandrogen. Also provided by the present invention is a kit for treating a human male, including a means for necrosing prostate tissue, an antiandrogen drug, and a means for administering the antiandrogen drug.Type: GrantFiled: July 9, 2002Date of Patent: March 21, 2006Assignee: American Medical Systems, Inc.Inventors: M. Alejandro Sousa Escandon, Johann J. Neisz
-
Patent number: 6992106Abstract: The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.Type: GrantFiled: June 12, 2002Date of Patent: January 31, 2006Assignee: Ajinomoto Co., Inc.Inventors: Yoshihiro Morinaga, Yukio Nihei, Yasuyo Suga, Manabu Suzuki, Kazuo Ohishi, Akira Okano
-
Patent number: 6977250Abstract: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as estrogen products.Type: GrantFiled: September 17, 2001Date of Patent: December 20, 2005Assignee: New Life Pharmaceuticals Inc.Inventor: Gustavo C. Rodriguez
-
Patent number: 6974568Abstract: The invention discloses the existence of cannabinoid receptors in the airways, which are functionally linked to inhibition of cough. Locally acting cannabinoid agents can be administered to the airways of a subject to ameliorate cough, without causing the psychoactive effects characteristic of systemically administered cannabinoids. In addition, locally or systemically administered cannabinoid inactivation inhibitors can also be used to ameliorate cough. The present invention also defines conditions under which cannabinoid agents can be administered to produce anti-tussive effects devoid of bronchial constriction.Type: GrantFiled: May 23, 2001Date of Patent: December 13, 2005Assignee: The Regents of the University of CaliforniaInventor: Daniele Piomelli